Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Mar 5;166(5):616-23.

Advances in the pharmacotherapy of Alzheimer's disease

Serge Gauthier  1
Affiliations
Review

Advances in the pharmacotherapy of Alzheimer's disease

Serge Gauthier. CMAJ. .
No abstract available

PubMed Disclaimer

Figures

None
Fig. 1: Synthesis of the neurotransmitter acetylcholine (ACh) from acetyl coenzyme A (AcCoA) and choline through the action of the enzyme choline acetyltransferase (ChAT). Acetylcholine is released into the synaptic cleft and acts on multiple sites including presynaptic nicotinic (N) and muscarinic type 2 (M2) receptors — exerting positive (+) and negative (–) action on further release of acetylcholine — and postsynaptic muscarinic type 1 (M1) receptors. Acetylcholinesterase (AChE) breaks acetylcholine down into choline and acetate. Photo by: Christine Kenney
None
Fig. 2: Projections from the nucleus basalis of Meynert and other cholinergic cell groups in the septum pellucidum to the hippocampus and neocortex. Photo by: Christine Kenney
None
Fig. 3: Global impression of change. Clinician's interview-based impression, with caregiver input, of change in global function. Least squares (LS) mean change from baseline scores (and standard error [SE]) for donepezil- and placebo-treated patients through 24 weeks of treatment. LOCF = last observation carried forward. Reprinted, with permission, from Feldman et al. Copyright © 2001 AAN Enterprises, Inc
None
Fig. 4: Disability Assessment for Dementia. LS mean change from baseline scores (and SE) for donepezil- and placebo-treated patients through 24 weeks of treatment. Reprinted, with permission, from Feldman et al. Copyright © 2001 AAN Enterprises, Inc
None
Fig. 5: Mean change from baseline scores (and SE) on cognitive subscale of Alzheimer's Disease Assessment Scale for galantamine- and placebo-treated patients over time. Reprinted, with permission, from Wilcock et al. Copyright © 2000 BMJ Publishing Group
See this image and copyright information in PMC

References

    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: The Association; 1994.
    1. Reisberg B, Ferris SH, DeLeon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9. - PubMed
    1. Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-98. - PubMed
    1. White P, Hiley CR, Goodhardt MJ, Carrasco LH, Keet JP, Williams IE, et al. Neocortical cholinergic neurons in elderly people. Lancet 1977;1:668-71. - PubMed
    1. Quirion R, Aubert I, Robitaille Y, Gauthier S, Araujo DM, Chabot JG. Neurochemical deficits in pathological brain aging: specificity and possible relevance for treatment strategies. Clin Neuropharmacol 1990;13(Suppl 3):S73-80. - PubMed

Publication types

MeSH terms

Substances